타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Keytruda (pembrolizumab) | Opdivo (nivolumab) | Herceptin (trastuzumab) | Imfinzi (durvalumab) |
Overview Company | Roche / Genentech | Merck | Bristol Myers Squibb | Roche / Genentech | AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | VEGF-A | PD-1 | PD-1 | HER2 | PD-L1 |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Multiple solid tumors | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m |
Positioning Known limitation | downregulation across different drug combinations | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | escape detection by the immune system |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | PD-1 with slow dissociation and preferential binding in TME-mimicking low | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. |
Toxicology Species | — | Cynomolgus monkey, Macaque, Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Rat | Cynomolgus monkey, Macaque, Mouse |
Toxicology Animal (cat.) | — | — | NHP | — | — |
Toxicology Major finding | — | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Toxicology CRS | — | N/A | N/A (checkpoint inhibitor) | N/A | N/A |
Clinical Safety signal | — | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | — | — | Mouse, In vitro | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Keytruda (pembrolizumab) | Opdivo (nivolumab) | Herceptin (trastuzumab) | Imfinzi (durvalumab) |
Overview Company | Roche / Genentech | Merck | Bristol Myers Squibb | Roche / Genentech | AstraZeneca |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | VEGF-A | PD-1 | PD-1 | HER2 | PD-L1 |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Multiple solid tumors | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m |
Positioning Known limitation | downregulation across different drug combinations | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | escape detection by the immune system |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | PD-1 with slow dissociation and preferential binding in TME-mimicking low | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. |
Toxicology Species | — | Cynomolgus monkey, Macaque, Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Rat | Cynomolgus monkey, Macaque, Mouse |
Toxicology Animal (cat.) | — | — | NHP | — | — |
Toxicology Major finding | — | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Toxicology CRS | — | N/A | N/A (checkpoint inhibitor) | N/A | N/A |
Clinical Safety signal | — | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | — | — | Mouse, In vitro | — |
추천 비교
추천 비교